Gender differences in symptoms, functioning and social support in patients at ultra-high risk for developing a psychotic disorder
Introduction
Studies have consistently shown there are gender differences in age of onset, severity of negative symptoms, long-term functioning and social support for patients with schizophrenia (Angermeyer et al., 1990, Bardenstein and McGlashan, 1990, DeLisi et al., 1989, Goldstein and Link, 1988, Grossman et al., 2006, Hambrecht et al., 1992, Lindamer et al., 2003, Shtasel et al., 1992, Usall et al., 2003). Some of these differences have also been observed in individuals with schizotypal personality disorder and other schizophrenia spectrum disorders (Dickey et al., 2005, Gurrera et al., 2005). However, it is not currently known if gender differences in clinical presentation and functioning are present prior to the development of psychosis.
To date, only one study (Amminger et al., 2006) has examined gender differences in adolescents who are at ultra-high-risk (UHR) for an imminent onset of psychosis. This study found that female sex was a significant predictor of conversion to affective psychosis 2-years after ascertainment. In addition, a second study (Nordentoft et al., 2006) found that, among young adults with a diagnosis of schizotypal disorder, males had a four-fold risk for conversion to schizophrenia 1-year after enrollment when compared to females. However, the findings of this study may not be directly comparable to a UHR population since diagnosis of schizotypal disorder allows for transient symptoms at the fully psychotic level. To our knowledge, no research to date has examined whether early clinical presentation or functioning differs between UHR males and females.
The current study focused on the clinical presentation of male and female patients who are UHR for developing a psychotic disorder. The primary goal was to determine if consistent relationships between gender, age at referral, psychosocial functioning, social support, and negative symptoms that are observed across phases of psychotic illness are also present in UHR youth. Second, we wanted to determine whether differences in negative symptoms are related to differences in later functioning and course of illness in UHR youth.
Section snippets
Subjects
All research was conducted at the Staglin Music Festival Center for the Assessment and Prevention of Prodromal States (CAPPS) at the University of California, Los Angeles. UHR participants were recruited primarily by clinical referral from local mental health providers, school psychologists or counselors, and by self-referral in response to advertisements or the CAPPS website. Potential subjects were screened over the phone and told that the program was recruiting individuals who had
Demographic variables
Demographic and attrition data can be found in Table 1. There were no significant differences between male and female participants on any demographic factors at baseline. There was also no significant difference in drop-out rates between male and female participants enrolled in this study.
Information on baseline medications can be found in Table 2. There were no differences in the number of males and females taking psychiatric medications at baseline, or in the average number of medications
Discussion
Within the sample of UHR patients, males appeared to have more severe negative symptoms and lower functioning than females, when data from all three time points was examined. The absence of differences between males and females at baseline suggests that differences in negative symptoms and functioning in UHR patients may be subtle but remain stable over time. Although the sample size was very small, incorporating data from follow-up time points decreased measurement error, thus providing a more
Role of funding source
This research was supported by NIMH grants MH65079, MH066286, and 5-T32-MH14584, and by a gift from the Staglin Music Festival for Mental Health.
Contributors
Ms. Willhite formulated the hypothese, conducted all analyses and wrote the manuscript. Drs. Niendam, Bearden and O'Brien assisted in organizing the database and editing the manuscript as did Ms. Zinberg. Dr. Cannon was instrumental in organizing the study and allowing Ms. Willhite to have access to the data. Dr. Cannon also assisted in the statistical analyses and helped to edit the manuscript.
Conflict of interest
None of the authors received any funding from sources that would provide a conflict of interest with regard to this research.
Acknowledgement
The authors would like to thank Malin McKinley, Adrienne Gallet and Maria Garcia for all of their hard work and significant contributions toward the study.
References (37)
- et al.
Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals
Schizophr. Res.
(2006) - et al.
Gender differences in affective, schizoaffective, and schizophrenic disorders: a review
Schizophr. Res.
(1990) - et al.
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder
Psychiatry Res.
(2002) - et al.
Gender differences in the brain: are they relevant to the pathogenesis of schizophrenia?
Compr. Psychiatry
(1989) - et al.
Clinical, cognitive, and social characteristics of a sample of neuroleptic-naive persons with schizotypal personality disorder
Schizophr. Res.
(2005) - et al.
Gender and the expression of schizophrenia
J. Psychiatr. Res.
(1988) - et al.
Sex differences in clinical response to olanzapine compared with haloperidol
Psychiatry Res.
(2002) - et al.
Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability
Biol. Psychiatry
(2007) - et al.
The five-factor model in schizotypal personality disorder
Schizophr. Res.
(2005) - et al.
Hormonal aspects of schizophrenias: an overview
Psychoneuroendocrinology
(2003)
Global assessment of functioning. A modified scale
Psychosomatics
Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis
Schizophr. Res.
Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment
Schizophr. Res.
Positive family environment predicts improvement in symptoms and social functioning among adolescents at imminent risk for onset of psychosis
Schizophr. Res.
The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia
Clin. Psychol. Rev.
Gender differences in the clinical expression of schizophrenia
Schizophr. Res.
Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample
Eur. Psychiatry
The functional significance of symptomatology and cognitive function in schizophrenia
Schizophr. Res.
Cited by (86)
Sex differences in bipolar disorder: The dorsolateral prefrontal cortex as an etiopathogenic region
2024, Frontiers in NeuroendocrinologyAssociation of perceived social support with sociodemographic, clinical, and psychosocial variables in patients with first-episode psychosis
2023, Journal of Psychiatric ResearchSchizophrenia spectrum and other psychotic disorders
2020, Handbook of Clinical NeurologyGender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study
2019, European PsychiatryCitation Excerpt :Regarding psychopathology, our findings were in line with a previous study of our own group that reported no gender differences in psychopathology, neither in ARMS nor in FEP patients, when corrected for multiple testing [26]. Furthermore, Willhite et al. [27] also found no significant gender differences in ratings of any of the symptoms of the Scale of Prodromal Symptoms (SOPS) in high-risk patients. A possible explanation may be that gender differences in the symptoms are so small that they can only be reliably detected in studies with very high statistical power (i.e. in very large datasets or in meta-analyses).